Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

Katherine R. Tuttle, Janeti B. McGill, Douglas J. Haney, Toni E. Lin, Pamela W. Anderson

Research output: Contribution to journalArticle

67 Scopus citations


Background: A pilot study showed that ruboxistaurin (RBX), a protein kinase C β inhibitor, significantly decreased albuminuria and stabilized kidney function over 1 yr in patients who had diabetic nephropathy and persistent macroalbuminuria despite receiving the current standard of care, including renin-angiotensin system inhibition. In contrast, in a trial of patients with diabetic retinopathy, investigators reported the adverse event "diabetic nephropathy" more frequently in patients who received RBX. Design, setting, participants, and measurements: The purpose of this study was to evaluate long-term effects of RBX on kidney outcomes among patients with diabetic eye disease in three diabetic retinopathy trials (n = 1157). Baseline-to-study end changes in estimated GFR (eGFR) were calculated. Kidney outcomes included doubling of serum creatinine, development of advanced chronic kidney disease (stages 4 to 5), and death. Results: Baseline eGFR was 81.6 ± 26.0 ml/min per 1.73 m2. In the combined placebo and RBX treatment groups, eGFR decreased by 11.0 ± 19.6 ml/min per 1.73 m2 during median follow-up of 33 to 39 mo. At least one kidney outcome occurred in 11.3% of patients. Frequency of doubling of serum creatinine was 6.0%, progression to advanced chronic kidney disease was 4.1%, and death was 4.1%. Kidney outcome rates did not differ by treatment assignment. Conclusions: Long-term kidney outco mes in patients with diabetic eye disease were similar in placebo and RBX groups. In conclusion, large-scale, prospective trials in patients with diabetic nephropathy are needed to confirm safety and potential benefits of RBX on clinical outcomes.

Original languageEnglish
Pages (from-to)631-636
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Issue number4
StatePublished - Jul 1 2007

Fingerprint Dive into the research topics of 'Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease'. Together they form a unique fingerprint.

  • Cite this